Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.50
Bid: 34.00
Ask: 37.00
Change: 2.00 (5.97%)
Spread: 3.00 (8.824%)
Open: 33.50
High: 36.00
Low: 33.00
Prev. Close: 33.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: YouGov, Sareum and InterQuest...

Tue, 07th Aug 2012 11:25

Environmental Recycling Technologies, which owns the rights to the Powder Impression Moulding (PIM) process which is capable of converting mixed waste plastics into commercially viable products, has confirmed that its US parent application, entitled 'Process for Forming Plastic, Apparatuses for Forming Plastic and Articles Made Therefrom', has been granted by the US Patent Office. This is ERT's core patent in the US for the PIM process. Sareum, a specialist cancer drug discovery business, has said it notes the recent significant rise in its share price and has confirmed that "advanced stages of negotiations are taking place with a potential licencing partner". It added these "may or may not lead to a licencing agreement regarding one of the company's research programmes". Shares were up 184% on Tuesday, equal to 1.15p. The stock has gained 42% over the past year, and 163% in the past month. YouGov, the online market research firm, is anticipating that its operating profit will be in line with expectations with second half revenue similar to that achieved in the first half, reflecting the firm's focus on profitability in the German business and the expected end to a long-term contract in Iraq. The firm said its balance sheet remains strong with cash at July 31st of around £7.0m. TClarke, a building services company, reported a decline in pre-tax profit for the half year at £0.5m (2011: £1.4m) on revenues of £90.7m (2011: £92.6m), with the profit margin also lower at 0.5% compared to 1.5% the previous year. Basic earnings per share dropped from 2.38p to 0.79p, while net cash climbed £0.1m to £0.7m. The interim dividend was maintained at 1p per share. The firm blamed a lack of confidence across the sector for the declines and said that with a number of projects due to begin shortly it is confident of significant revenue progress in the second half. Shares in InterQuest Group, a specialist information technology recruitment group, took a hit after it admitted earnings before interest, tax, depreciation and amortisation are expected to be down year-on-year, in the region of £1.15m (2011: £1.86m), and warned the impact of investments and restructuring on profitability for 2012 will be around £1.6m. Trading conditions were poor in both the UK and Far East, particularly in the second quarter and particularly in the banking and finance sectors from which it derives 27% of its net fee income. This has meant profitability from investments has taken longer than anticipated. NR
More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.